Table 4 The predicted acceptance (latent class model) when risk of severe side effects is fixed at 1 out of 1000 and 50 patients received treatment for the different classes with the hESCs as the type of treatment
hESCs (%) | ||||
|---|---|---|---|---|
Class 1 | Class 2 | Class 3 | ||
Effect on symptoms 2 out of 10 | ||||
Symptom relief | 79 | 98 | 72 | |
Slow down disease progression | 81 | 99 | 88 | |
Repair damage caused by disease | 82 | 100 | 88 | |
Effect on symptoms 5 out of 10 | ||||
Symptom relief | 85 | 85 | 79 | |
Slow down disease progression | 91 | 100 | 90 | |
Repair damage caused by disease | 91 | 100 | 90 | |
Effect on symptoms 8 out of 10 | ||||
Symptom relief | 94 | 100 | 75 | |
Slow down disease progression | 95 | 100 | 90 | |
Repair damage caused by disease | 95 | 100 | 90 | |